390 related articles for article (PubMed ID: 31354710)
1. Invariant NKT Cells From Donor Lymphocyte Infusions (DLI-iNKTs) Promote
Jahnke S; Schmid H; Secker KA; Einhaus J; Duerr-Stoerzer S; Keppeler H; Schober-Melms I; Baur R; Schumm M; Handgretinger R; Bethge W; Kanz L; Schneidawind C; Schneidawind D
Front Immunol; 2019; 10():1542. PubMed ID: 31354710
[TBL] [Abstract][Full Text] [Related]
2. Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effects.
Giver CR; Montes RO; Mittelstaedt S; Li JM; Jaye DL; Lonial S; Boyer MW; Waller EK
Biol Blood Marrow Transplant; 2003 Oct; 9(10):616-32. PubMed ID: 14569558
[TBL] [Abstract][Full Text] [Related]
3. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras.
Xia G; Truitt RL; Johnson BD
Biol Blood Marrow Transplant; 2006 Apr; 12(4):397-407. PubMed ID: 16545723
[TBL] [Abstract][Full Text] [Related]
4. [Alloreactive donor lymphocytes (DLI) after allogeneic hematopoietic stem cell transplantation (HSCT): study of toxicity and efficacy].
Michallet AS; Nicolini F; Michallet M
Bull Cancer; 2003; 90(8-9):758-62. PubMed ID: 14609766
[TBL] [Abstract][Full Text] [Related]
5. Early posttransplantation donor-derived invariant natural killer T-cell recovery predicts the occurrence of acute graft-versus-host disease and overall survival.
Rubio MT; Moreira-Teixeira L; Bachy E; Bouillié M; Milpied P; Coman T; Suarez F; Marcais A; Sibon D; Buzyn A; Caillat-Zucman S; Cavazzana-Calvo M; Varet B; Dy M; Hermine O; Leite-de-Moraes M
Blood; 2012 Sep; 120(10):2144-54. PubMed ID: 22730537
[TBL] [Abstract][Full Text] [Related]
6. Herpes simplex thymidine kinase gene-transduced donor lymphocyte infusions.
Burt RK; Drobyski WR; Seregina T; Traynor A; Oyama Y; Keever-Taylor C; Stefka J; Kuzel TM; Brush M; Rodriquez J; Burns W; Tennant L; Link C
Exp Hematol; 2003 Oct; 31(10):903-10. PubMed ID: 14550806
[TBL] [Abstract][Full Text] [Related]
7. Donor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantation.
Luznik L; Fuchs EJ
Cancer Control; 2002; 9(2):123-37. PubMed ID: 11965233
[TBL] [Abstract][Full Text] [Related]
8. On the use of donor-derived iNKT cells for adoptive immunotherapy to prevent leukemia recurrence in pediatric recipients of HLA haploidentical HSCT for hematological malignancies.
Dellabona P; Casorati G; de Lalla C; Montagna D; Locatelli F
Clin Immunol; 2011 Aug; 140(2):152-9. PubMed ID: 21185785
[TBL] [Abstract][Full Text] [Related]
9. G-CSF administration prior to donor lymphocyte apheresis promotes anti-leukaemic effects in allogeneic HCT patients.
Schneidawind C; Jahnke S; Schober-Melms I; Schumm M; Handgretinger R; Faul C; Kanz L; Bethge W; Schneidawind D
Br J Haematol; 2019 Jul; 186(1):60-71. PubMed ID: 30916396
[TBL] [Abstract][Full Text] [Related]
10. Distinct graft-versus-leukemic stem cell effects of early or delayed donor leukocyte infusions in a mouse chronic myeloid leukemia model.
Lu YF; Gavrilescu LC; Betancur M; Lazarides K; Klingemann H; Van Etten RA
Blood; 2012 Jan; 119(1):273-84. PubMed ID: 22072555
[TBL] [Abstract][Full Text] [Related]
11. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
12. The role of invariant NKT cells in allogeneic hematopoietic stem cell transplantation.
Karadimitris A; Chaidos A
Crit Rev Immunol; 2012; 32(2):157-71. PubMed ID: 23216613
[TBL] [Abstract][Full Text] [Related]
13. Strategies for Enhancing and Preserving Anti-leukemia Effects Without Aggravating Graft-Versus-Host Disease.
Chang YJ; Zhao XY; Huang XJ
Front Immunol; 2018; 9():3041. PubMed ID: 30619371
[TBL] [Abstract][Full Text] [Related]
14. Graft-versus-leukemia effects from donor lymphocyte infusion after nonmyeloablative allogeneic bone marrow transplantation in mice.
Du B; Li DP; Xu KL; Pan XY
Chin Med J (Engl); 2005 Mar; 118(6):474-9. PubMed ID: 15788128
[TBL] [Abstract][Full Text] [Related]
15. Sequential infusion of donor-derived dendritic cells with donor lymphocyte infusion for relapsed hematologic cancers after allogeneic hematopoietic stem cell transplantation.
Ho VT; Kim HT; Kao G; Cutler C; Levine J; Rosenblatt J; Joyce R; Antin JH; Soiffer RJ; Ritz J; Avigan D; Alyea EP
Am J Hematol; 2014 Dec; 89(12):1092-6. PubMed ID: 25132538
[TBL] [Abstract][Full Text] [Related]
16. Culture-Expanded Human Invariant Natural Killer T Cells Suppress T-Cell Alloreactivity and Eradicate Leukemia.
Schmid H; Schneidawind C; Jahnke S; Kettemann F; Secker KA; Duerr-Stoerzer S; Keppeler H; Kanz L; Savage PB; Schneidawind D
Front Immunol; 2018; 9():1817. PubMed ID: 30127790
[TBL] [Abstract][Full Text] [Related]
17. Invariant natural killer T cells in hematopoietic stem cell transplantation: killer choice for natural suppression.
Guan P; Bassiri H; Patel NP; Nichols KE; Das R
Bone Marrow Transplant; 2016 May; 51(5):629-37. PubMed ID: 26878658
[TBL] [Abstract][Full Text] [Related]
18. Preemptive cellular immunotherapy after T-cell-depleted allogeneic hematopoietic stem cell transplantation.
Baron F; Beguin Y
Biol Blood Marrow Transplant; 2002; 8(7):351-9. PubMed ID: 12171481
[TBL] [Abstract][Full Text] [Related]
19. Experimental and clinical approaches for optimization of the graft-versus-leukemia effect.
Sprangers B; Van Wijmeersch B; Fevery S; Waer M; Billiau AD
Nat Clin Pract Oncol; 2007 Jul; 4(7):404-14. PubMed ID: 17597705
[TBL] [Abstract][Full Text] [Related]
20. Donor lymphocyte infusion: the use of alloreactive and tumor-reactive lymphocytes for immunotherapy of malignant and nonmalignant diseases in conjunction with allogeneic stem cell transplantation.
Slavin S; Morecki S; Weiss L; Or R
J Hematother Stem Cell Res; 2002 Apr; 11(2):265-76. PubMed ID: 11983098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
